20240024362. DONOR HEMATOPOIETIC CELL CHIMERISM AND ORGAN AND TISSUE TRANSPLANTATION AND AUTOIMMUNE TOLERANCE simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
Contents
DONOR HEMATOPOIETIC CELL CHIMERISM AND ORGAN AND TISSUE TRANSPLANTATION AND AUTOIMMUNE TOLERANCE
Organization Name
The Board of Trustees of the Leland Stanford Junior University
Inventor(s)
Robert Lowsky of Stanford CA (US)
Samuel Strober of Portola Valley CA (US)
Everett Hurteau Meyer of Belmont CA (US)
Kent Jensen of Redwood City CA (US)
Stephan Busque of Stanford CA (US)
DONOR HEMATOPOIETIC CELL CHIMERISM AND ORGAN AND TISSUE TRANSPLANTATION AND AUTOIMMUNE TOLERANCE - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240024362 titled 'DONOR HEMATOPOIETIC CELL CHIMERISM AND ORGAN AND TISSUE TRANSPLANTATION AND AUTOIMMUNE TOLERANCE
Simplified Explanation
The patent application describes compositions and methods for organ and tissue transplantation and autoimmune tolerance using the infusion of living and/or deceased donor hematopoietic cells. The methods involve conditioning with multiple doses of total lymphoid irradiation (TLI) and a single, very low dose of total body irradiation (TBI), referred to as "TLI-SVLDTBI-ATG" or "TLI-SVLDTBI" depending on whether anti-thymocyte globulin (ATG) is included. This combination specifically targets non-lymphoid-tissue resident memory immune cells.
Key points of the patent/innovation:
- Compositions and methods for organ and tissue transplantation and autoimmune tolerance.
- Infusion of living and/or deceased donor hematopoietic cells.
- Conditioning with multiple doses of TLI and a single, very low dose of TBI.
- Targeting non-lymphoid-tissue resident memory immune cells.
- In vitro manipulated donor cell composition with specific ratios of CD34 and other hematopoietic stem cell and precursor cell populations combined with defined doses of CD3 T cells, regulatory T cells (Treg), invariant natural killer (INK-T) cells, and/or CD8 memory T cells.
Potential applications of this technology:
- Organ and tissue transplantation: The methods described in the patent application can potentially improve the success rate of organ and tissue transplantation by achieving autoimmune tolerance and reducing the risk of rejection.
- Autoimmune diseases: The infusion of donor hematopoietic cells and the conditioning regimen may also be applicable in the treatment of autoimmune diseases by modulating the immune response and promoting tolerance.
Problems solved by this technology:
- Rejection in organ and tissue transplantation: The conditioning regimen and infusion of specific donor cells aim to reduce the risk of rejection and improve the acceptance of transplanted organs and tissues.
- Autoimmune diseases: The methods described in the patent application offer a potential solution for managing autoimmune diseases by inducing tolerance and suppressing the immune response.
Benefits of this technology:
- Improved success rate of organ and tissue transplantation: By targeting non-lymphoid-tissue resident memory immune cells, the conditioning regimen and infusion of donor cells may enhance the acceptance of transplanted organs and tissues, leading to improved outcomes for patients.
- Potential treatment for autoimmune diseases: The methods described in the patent application offer a novel approach to modulating the immune response and promoting tolerance in autoimmune diseases, potentially providing new treatment options for patients.
Original Abstract Submitted
compositions and methods are provided for the achievement of organ and tissue transplantation and autoimmune tolerance using the infusion of living and/or deceased donor hematopoietic cells. the methods provided herein provide for conditioning with a plurality of doses of total lymphoid irradiation (tli), and a single, very low dose of tbi (svldtbi), referred to herein as “tli-svldtbi-atg” or “tli-svldtbi” depending on whether atg is included. the combination of svldtbi and tli specifically targets non-lymphoid-tissue resident memory immune cells. an in vitro manipulated donor cell composition is provided for use with the conditioning regimen, in which specific ratios of cd34 and other hematopoietic stem cell and precursor cell populations are combined with defined doses of cd3 t cells, and/or purified regulatory t cells (treg) cells, invariant natural killer (ink-t) cells, and/or cd8 memory t cells.
